Loading...
Please wait, while we are loading the content...
Similar Documents
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
| Content Provider | MDPI |
|---|---|
| Author | Florence, Boissière-Michot Jacot, William Maran-Gonzalez, Aurélie Massol, Océane Sorbs, Charlotte Mollevi, Caroline Guiu, Séverine Ramos, Jeanne |
| Copyright Year | 2021 |
| Description | HER2-low breast cancer (i.e., HER 1+ or 2+, without gene amplification) is an emerging subtype for which very few data are available, especially within the triple-negative breast cancer (TNBC) group. Our aim was to evaluate HER2 expression and its prognostic value in a large retrospective series of patients with non-metastatic TNBC (median age: 57.7 years; range: 28.5–98.6). Among the 296 TNBC samples, 83.8% were HER2 0, 13.5% were HER2 1+, and 2.7% were HER2 2+ $(HercepTest^{TM}$ and 2018 ASCO/CAP guidelines for HER2 scoring). CK5/6 and/or EGFR-expressing androgen receptors and FOXA1-expressing tumors were classified as basal-like (63.8%) and molecular apocrine-like (MA, 40.2%), respectively. Compared with HER2 0 tumors, HER2 1+/2+ tumors exhibited a lower histological grade (1/2) (35.4% vs. 18.2%, p = 0.007) and MA profile (57.5% vs. 36.7%, p = 0.008). Moreover, patients with HER2 1+/2+ tumors were older (p = 0.047). After a median follow-up of 9.7 years, HER2 2+ tumors (compared with HER2 0/1+ tumors) were associated with worse relapse-free survival (RFS) (HR = 3.16, 95% CI [1.27; 7.85], p = 0.034) in a univariate analysis. Overall survival (OS) and RFS were not different in the HER2 0 and 1+/2+ groups. HER2 levels were not significantly associated with OS or RFS in a multivariate analysis. |
| Starting Page | 6059 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13236059 |
| Journal | Cancers |
| Issue Number | 23 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-12-01 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Triple-negative Breast Cancer Her2-low Expression Prognosis Molecular Apocrine Androgen Receptor |
| Content Type | Text |
| Resource Type | Article |
